VOR completes Phase III telitacicept enrollment; key readout set for early 2027
VOR says enrollment is complete for its Phase III telitacicept MG trial, with a key readout expected in early 2027. The company is expanding into ocular MG and Sjögren’s, highlighting a dual BAFF/APRIL mechanism.